New contrast agent could sharpen pancreatic cancer scans
NCT ID NCT07597772
First seen May 22, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This early-phase study tests a new contrast agent (68Ga-labelled claudin 18.2) used with PET/CT scans to better see pancreatic cancer. About 12 adults with pancreatic cancer will receive the agent to check its safety and how well it targets tumors. The goal is to improve cancer imaging, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
Conditions
Explore the condition pages connected to this study.